Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/7/2022 | $12.00 | Buy | Guggenheim |
| 2/11/2022 | $10.00 | Neutral | Goldman |
| 7/12/2021 | $18.00 | Buy | Canaccord Genuity |
| 7/12/2021 | $16.00 | Buy | Truist Securities |
| 7/12/2021 | $21.00 | Buy | Goldman |
| 7/12/2021 | $15.00 | Buy | BofA Securities |
| 7/12/2021 | $16.00 | Overweight | Barclays |
| 7/12/2021 | $12.00 | Neutral | JP Morgan |
SC 13G/A - Convey Health Solutions Holdings, Inc. (0001787640) (Subject)
4 - Convey Health Solutions Holdings, Inc. (0001787640) (Issuer)
4 - Convey Health Solutions Holdings, Inc. (0001787640) (Issuer)
4 - Convey Health Solutions Holdings, Inc. (0001787640) (Issuer)
Convey Taken Private by TPG for $10.50 per Share in Cash FORT LAUDERDALE, Fla., Oct. 7, 2022 /PRNewswire/ -- Convey Health Solutions Holdings, Inc. (NYSE:CNVY) ("Convey"), a leading healthcare technology and services company, announced today the closing of its acquisition by TPG Capital, the large-scale U.S. and European private equity platform of alternative asset management firm TPG. On June 21, 2022, Convey announced that TPG Capital had signed a definitive agreement to acquire all of the outstanding shares of Convey common stock not currently owned by TPG or certain manage
Convey Shareholders to Receive $10.50 per Share in Cash, Representing a 99% Premium Over Convey's 30-Day Volume Weighted Average Price FORT LAUDERDALE, Fla., June 21, 2022 /PRNewswire/ -- Convey Health Solutions Holdings, Inc. (NYSE:CNVY) ("Convey"), a leading healthcare technology and services company, announced today that it has entered into a definitive merger agreement pursuant to which TPG Capital, the private equity platform of global alternative asset management firm TPG ("TPG") and Convey's principal shareholder, will acquire all of the outstanding shares of Convey common stock not currently owned by TPG or certain management and director shareholders for $10.50 per share in cash, re
First Quarter 2022 Highlights Net revenues of $96.7 million, up 17% compared to Q1 2021 of $82.6 millionNet loss of $1.2 million, which includes $1.6 million of HealthSmart purchase accounting and acquisition related expenses, compared to Q1 2021 net loss of $0.9 millionAdjusted EBITDA of $15.3 million, compared to Q1 2021 of $15.9 millionFORT LAUDERDALE, Fla., May 10, 2022 /PRNewswire/ -- Convey Health Solutions Holdings, Inc. (NYSE:CNVY) (the "Company" or "Convey"), a leading healthcare technology and services company in the U.S., announced today financial results for the first quarter ended March 31, 2022.
Guggenheim initiated coverage of Convey Health with a rating of Buy and set a new price target of $12.00
Goldman initiated coverage of Convey Health with a rating of Neutral and set a new price target of $10.00
Canaccord Genuity initiated coverage of Convey Health with a rating of Buy and set a new price target of $18.00
15-12G - Convey Health Solutions Holdings, Inc. (0001787640) (Filer)
S-8 POS - Convey Health Solutions Holdings, Inc. (0001787640) (Filer)
S-8 POS - Convey Health Solutions Holdings, Inc. (0001787640) (Filer)
Upgrades RBC Capital upgraded the previous rating for SiteOne Landscape Supply Inc (NYSE:SITE) from Underperform to Sector Perform. In the first quarter, SiteOne Landscape Supply showed an EPS of $0.70, compared to $0.19 from the year-ago quarter. At the moment, the stock has a 52-week-high of $260.00 and a 52-week-low of $108.77. SiteOne Landscape Supply closed at $112.24 at the end of the last trading period. JP Morgan upgraded the previous rating for Brixmor Property Group Inc (NYSE:BRX) from Neutral to Overweight. In the first quarter, Brixmor Property Group showed an EPS of $0.49, compared to $0.44 from the year-ago quarter. The current stock performance of Brixmor Property Group sho
Guggenheim analyst Sandy Draper downgrades Convey Health Solutions (NYSE:CNVY) from Buy to Neutral.
Barclays analyst Steve Valiquette downgrades Convey Health Solutions (NYSE:CNVY) from Overweight to Equal-Weight and lowers the price target from $12 to $11.
First Quarter 2022 Highlights Net revenues of $96.7 million, up 17% compared to Q1 2021 of $82.6 millionNet loss of $1.2 million, which includes $1.6 million of HealthSmart purchase accounting and acquisition related expenses, compared to Q1 2021 net loss of $0.9 millionAdjusted EBITDA of $15.3 million, compared to Q1 2021 of $15.9 millionFORT LAUDERDALE, Fla., May 10, 2022 /PRNewswire/ -- Convey Health Solutions Holdings, Inc. (NYSE:CNVY) (the "Company" or "Convey"), a leading healthcare technology and services company in the U.S., announced today financial results for the first quarter ended March 31, 2022.
FORT LAUDERDALE, Fla., May 3, 2022 /PRNewswire/ -- Convey Health Solutions Holdings, Inc. (NYSE:CNVY) ("Convey Health Solutions" or "Convey"), a leading healthcare technology and services company, announced today that it will issue a press release with first quarter 2022 financial results on Tuesday, May 10, 2022 after the market closes. In conjunction with the release, Convey will host a conference call to review these financial results at 4:30 p.m. (ET) on the same day. First Quarter 2022 Conference Call Details The conference call can be accessed by dialing (844) 200-6205 for U.S. participants, or +1 (929) 526-1599 for international participants, referencing access code 105506; or via a l
FORT LAUDERDALE, Fla., Feb. 23, 2022 /PRNewswire/ -- Convey Health Solutions Holdings, Inc. (NYSE:CNVY) ("Convey Health Solutions" or "Convey"), a leading healthcare technology and services company, announced today that it will issue a press release with fourth quarter and full year 2021 financial results and 2022 guidance on Wednesday, March 23, 2022 after the market closes. In conjunction with the release, Convey will host a conference call to review these financial results at 5:00 p.m. (ET) on the same day. Fourth Quarter and Full Year 2021 Conference Call Details The confe
FORT LAUDERDALE, Fla., Feb. 15, 2022 /PRNewswire/ -- Convey Health Solutions Holdings, Inc. (NYSE:CNVY) ("Convey"), a leading healthcare technology and services company, today announced the appointment of Paul Campanelli to its Board of Directors ("Board"). Mr. Campanelli has approximately 30 years of experience in the healthcare industry, including leadership positions in both publicly held and private equity controlled companies. Mr. Campanelli previously served as Chairman of the Board of Endo International ("Endo") from November 2019 to June 2021, and previously served as